| Recruiting | Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance NCT07285057 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Not Yet Recruiting | Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions ( NCT07483658 | CHU de Quebec-Universite Laval | N/A |
| Recruiting | A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer NCT07319871 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture NCT07335224 | Inova Health Care Services | N/A |
| Recruiting | A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in Fra NCT07451002 | Janssen Cilag S.A.S. | — |
| Recruiting | Prostate Adaptive Radiation Therapy NCT06547398 | Royal North Shore Hospital | N/A |
| Not Yet Recruiting | Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer NCT07104110 | Qilu Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway NCT07406282 | Bayer | — |
| Recruiting | A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer NCT07082920 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) NCT06925737 | Merck Sharp & Dohme LLC | Phase 3 |
| Not Yet Recruiting | PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique NCT06914427 | Xijing Hospital | N/A |
| Recruiting | A Study of DM002 in Patients With Advanced Solid Tumors NCT06751329 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | Phase 1 |
| Recruiting | Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 NCT06785636 | Pathos AI, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Real-life Experience in Brazil in Patients With Castration-resistant Prostate Cancer Treated With Olaparib+Abi NCT06457854 | AstraZeneca | — |
| Recruiting | 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prost NCT06706921 | VA Greater Los Angeles Healthcare System | Phase 4 |
| Not Yet Recruiting | Prognostic Study of Prostate Cancer Via Dynamic Change of PSA in Peritoneal Drainage Fluid After Radical Prost NCT06608225 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Not Yet Recruiting | Prognostic Study of Via Dynamic Change of PCA3 mRNA in Drainage Fluid After Radical Prostatectomy NCT06707961 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Not Yet Recruiting | Prognostic Study of Via Dynamic Change of dT-DNA in Drainage Fluid After Radical Prostatectomy NCT06707974 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Recruiting | Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation NCT06894628 | Regina Elena Cancer Institute | — |
| Withdrawn | SUPERvised Three-month Exercise Program in MEN With Prostate cAncer Receiving Androgen-deprivaTioN thERapy NCT06282185 | Canisius-Wilhelmina Hospital | N/A |
| Completed | A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011) NCT06554639 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Impact on Quality of Life and Health of the CONTINUUM+ CONNECT Remote Monitoring Solution NCT06379880 | Centre Paul Strauss | N/A |
| Terminated | Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy NCT05872503 | National Cancer Institute (NCI) | — |
| Recruiting | Clinical Application of the J-PET Scanner Prototype NCT06242119 | Jagiellonian University | — |
| Recruiting | RecoverPC: Relugolix vs GnRH Agonist in Quality of Life NCT05765500 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Prostate Hyperfixation on PET-choline in Patients With Prostate Cancer: Correlation With MRI and Pathological NCT06836154 | University Hospital, Brest | — |
| Recruiting | Effect of Hypoxia on FMISO PET to Response to Lu-177 PSMA Treatment NCT06433063 | Cigdem Soydal | N/A |
| Completed | A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (m NCT06136598 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient NCT06209853 | Assiut University | — |
| Completed | Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment NCT05999968 | Eli Lilly and Company | Phase 1 |
| Completed | Prospective Validation of Pathology-based Artificial Intelligence Diagnostic Model for Lymph Node Metastasis i NCT06253065 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Active Not Recruiting | Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Tri NCT05918263 | Dana-Farber Cancer Institute | N/A |
| Recruiting | Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Ra NCT06056830 | Clarity Pharmaceuticals Ltd | Phase 3 |
| Recruiting | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castrat NCT06136650 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Dose Escalation For INtraprostatic LEsions NCT05851547 | Ottawa Hospital Research Institute | Phase 2 |
| Completed | A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mC NCT06151418 | Pfizer | — |
| Active Not Recruiting | A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer NCT06104449 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor NCT05616650 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer NCT06072196 | Pfizer | — |
| Completed | PROWESS (PROstate Cancer Wearables Exercise and Structured Supports): A Pilot Supportive Care Intervention NCT05755490 | Massachusetts General Hospital | N/A |
| Completed | Effect of Changes in Endotracheal Tube Cuff Pressure on Postoperative Pharyngolaryngeal Complications in Robot NCT07242144 | Ege University | — |
| Unknown | The Effect of Frailty on Blood Biology Indicators, Quality of Life and Survival of Patients With Radical Prost NCT05941104 | Anhui Provincial Hospital | — |
| Completed | The Application Value of Prostate Specific Membrane Antigen PET/CT in Biopsy Free of PSA Grey Area Prostate Ca NCT05958004 | First Affiliated Hospital Xi'an Jiaotong University | — |
| Terminated | 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Ex NCT05633160 | Clarity Pharmaceuticals Ltd | Phase 1 / Phase 2 |
| Recruiting | Evaluation of Different Methods of Ultrasound Image Analysis for Real-time Monitoring of HIFU Prostate Cancer NCT05714774 | Hospices Civils de Lyon | N/A |
| Completed | The Efficacy of Mapping for Cognitive Prostate Biopsy NCT05902637 | Marmara University | N/A |
| Unknown | a Study of Combined mpMRI and PSMA PET/CT for Highly Suspicious Patients Performing Radical Prostatectomy With NCT05670691 | Fudan University | — |
| Recruiting | Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy NCT04833426 | Canisius-Wilhelmina Hospital | Phase 3 |
| Completed | A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer NCT05441501 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | Imperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for Canc NCT05574647 | Imperial College London | N/A |
| Recruiting | Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection NCT05413850 | Blue Earth Therapeutics Ltd | Phase 1 / Phase 2 |
| Completed | Effectiveness Evaluation of a Self-management Program for Prostate Cancer Survivors NCT05335967 | National Taipei University of Nursing and Health Sciences | N/A |
| Completed | Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe LUTS Due to BPH NCT05834270 | Menoufia University | N/A |
| Completed | The Role of the Seven Sweeps in the Prevention of the Prostate Cancer Among Those With a Positive Family Histo NCT05506735 | University of Baghdad | — |
| Unknown | EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRP NCT05150236 | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Phase 2 |
| Active Not Recruiting | A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts NCT05288166 | Eli Lilly and Company | Phase 3 |
| Active Not Recruiting | Contributions of a Paramedical Approach in the Prevention and Treatment of Side Effects Associated With Radica NCT05266313 | University Hospital Center of Martinique | N/A |
| Terminated | A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Cast NCT05295927 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | Lymphedema After Urologic Surgery NCT05264337 | Vastra Gotaland Region | — |
| Active Not Recruiting | Imperial Prostate 6 - Cancer Histology Artificial Intelligence Reliability Study. NCT05228197 | Imperial College London | — |
| Unknown | Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients NCT05068180 | RenJi Hospital | Phase 4 |
| Completed | Study of Diagnostic Performance of [18F]CTT1057 in BCR NCT04838613 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants NCT05022849 | Janssen Research & Development, LLC | Phase 1 |
| Active Not Recruiting | Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants NCT04964271 | Tethis S.p.A. | — |
| Completed | Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection NCT04838626 | Novartis Pharmaceuticals | Phase 2 / Phase 3 |
| Unknown | The Application Value of 18F-prostate-specific Membrane Antigen PET/CT in Prostate Cancer NCT04521894 | First Affiliated Hospital Xi'an Jiaotong University | — |
| Unknown | Preventing Catheter Related Bladder Discomfort (CRBD) With Bilateral Pudendal Nerve Block NCT05022160 | Armed Forces Hospital, Pakistan | EARLY_Phase 1 |
| Completed | A Study of CC-90011 and Comparators in Participants With Prostate Cancer NCT04628988 | Celgene | Phase 1 |
| Completed | Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPS NCT04839367 | Clarity Pharmaceuticals Ltd | Phase 1 |
| Active Not Recruiting | A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate NCT04898634 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | Randomized Pilot Study of Radiosurgery for the Treatment of Non-metastatic Prostate Cancer NCT05123391 | Pontificia Universidad Catolica de Chile | N/A |
| Active Not Recruiting | 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resi NCT04689828 | Novartis Pharmaceuticals | Phase 3 |
| Active Not Recruiting | An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination W NCT04720157 | Novartis Pharmaceuticals | Phase 3 |
| Unknown | 68Ga-PSMA PET in the Prostate Cancer NCT04967001 | Xijing Hospital | N/A |
| Unknown | Verification of Shear Wave Elastography for DEtection of Prostate Cancer NCT04836949 | Yonsei University | N/A |
| Completed | Combined PSMA PET/MRI for Detection of Lymph Node Metastases in High-risk Prostate Cancer Patients NCT04790968 | Norwegian University of Science and Technology | N/A |
| Completed | High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy NCT04461509 | Alessandro D'Agnolo | Phase 2 |
| Unknown | ComCancer: Use of Let's Discuss Health Website by Patients With Prostate Cancer Undergoing Radiation Oncology NCT05787145 | Ciusss de L'Est de l'Île de Montréal | N/A |
| Completed | Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer NCT04736199 | Bayer | Phase 3 |
| Active Not Recruiting | Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Pr NCT04295447 | Universität Münster | Phase 2 |
| Active Not Recruiting | Evaluation of Atherosclerotic Plaques in Abdominal CT Studies NCT04652973 | National Institutes of Health Clinical Center (CC) | — |
| Active Not Recruiting | A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer NCT04577833 | Janssen Research & Development, LLC | Phase 1 |
| Active Not Recruiting | A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Pros NCT04644770 | Janssen Research & Development, LLC | Phase 1 |
| Active Not Recruiting | A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Pr NCT04557059 | Janssen Pharmaceutica N.V., Belgium | Phase 3 |
| Terminated | Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic NCT04907227 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Intestinal Microbiota in Prostate Cancer Patients as a Biomarker for Radiation-INduced Toxicity (IMPRINT) NCT04638049 | University Hospital, Ghent | N/A |
| Completed | A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Un NCT04523207 | Janssen Research & Development, LLC | Phase 2 |
| Active Not Recruiting | Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy NCT04430192 | Peter MacCallum Cancer Centre, Australia | Phase 1 / Phase 2 |
| Terminated | Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Anti NCT04085991 | Sir Mortimer B. Davis - Jewish General Hospital | Phase 2 |
| Completed | Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mC NCT04425200 | AstraZeneca | — |
| Unknown | Effectiveness of 68Ga-PSMA PET/MRI for Improving the Detection of csPCa in Lesions With PI-RADS Score 3 NCT04573179 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | — |
| Completed | Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant NCT04428788 | Celgene | Phase 1 |
| Completed | PSMA-PET and MRI for Detection of Recurrent Prostate Cancer After Radical Treatment NCT04298112 | Norwegian University of Science and Technology | — |
| Enrolling By Invitation | Multiparametric MRI in Men With Prostate Cancer Enrolled in Active Surveillance NCT03648359 | Herlev Hospital | N/A |
| Terminated | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRP NCT04249947 | Poseida Therapeutics, Inc. | Phase 1 |
| Unknown | Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients NCT04248621 | Wonju Severance Christian Hospital | Phase 4 |
| Active Not Recruiting | A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CR NCT04108208 | Janssen Research & Development, LLC | Phase 4 |
| Not Yet Recruiting | Radical Prostatectomy Versus Radical Radiotherapy for Locally Advanced Prostate Cancer NCT04093375 | Tongji Hospital | N/A |
| Unknown | Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging NCT04017104 | British Columbia Cancer Agency | — |
| Terminated | Study of ORIC-101 in Combination With Enzalutamide NCT04033328 | ORIC Pharmaceuticals | Phase 1 |
| Unknown | Measurement of Circulating Tumor Cells in Prostate Cancer NCT04101305 | Sormland County Council, Sweden | — |
| Unknown | Rectal Gas Removal Through Small Catheter Placement Prior to MRI of the Prostate NCT03987737 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metas NCT03834493 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate NCT04034095 | Janssen Pharmaceutical K.K. | — |
| Active Not Recruiting | A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are C NCT03767244 | Janssen Research & Development, LLC | Phase 3 |
| Completed | Multimedia-based Hormonal Therapy Information Program for Patients With Prostate Cancer NCT04693910 | National Taipei University of Nursing and Health Sciences | N/A |
| Completed | Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic NCT03834506 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castra NCT03834519 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Treatment Satisfaction With Ra-223 in Japan NCT03315260 | Bayer | — |
| Recruiting | Men at High Genetic Risk for Prostate Cancer NCT03805919 | National Cancer Institute (NCI) | — |
| Completed | Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of NCT03822845 | Michael Graham PhD, MD | Phase 2 / Phase 3 |
| Active Not Recruiting | 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer NCT03824275 | Columbia University | Phase 2 / Phase 3 |
| Active Not Recruiting | Moderately Hypofractionated Radiotherapy for Prostate Cancer. NCT03827616 | Tatarstan Cancer Center | N/A |
| Completed | The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Pro NCT03436745 | National Cancer Institute (NCI) | Phase 1 |
| Completed | PSMA PET/CT for Biochemical Recurrence Detection in Patients With Prostate Cancer NCT04983459 | University Hospital, Brest | — |
| Unknown | A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prosta NCT03587285 | Guangzhou University of Traditional Chinese Medicine | Phase 1 / Phase 2 |
| Unknown | Analysis of Androgene Receptors Axis and DNA Damage Repair Genes in Patients With Prostate Cancer NCT03677414 | Medical University of Graz | — |
| Active Not Recruiting | A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Re NCT03523442 | Janssen Research & Development, LLC | Phase 1 |
| Completed | A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment NCT03572387 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Unknown | Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study NCT03600766 | Mansoura University | Phase 2 |
| Completed | Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Base NCT03481816 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | An Electronic Registry to Improve Adherence to Active Surveillance Monitoring at a Safety-net Hospital NCT03553732 | University of California, San Francisco | — |
| Unknown | Local Treatment With RP for Newly-diagnosed mPCa NCT02138721 | University Hospital, Ghent | N/A |
| Completed | Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer NCT03565835 | Montefiore Medical Center | Phase 2 |
| Unknown | Biomarkers in Prostate Cancer Treated With SRP Following Failure of FAT NCT03533998 | Institut Mutualiste Montsouris | — |
| Completed | A Study of Participants With Advanced Prostate Cancer in Canada NCT03501173 | Janssen Inc. | — |
| Unknown | Learning Curve of Digital Rectal Examination for Prostate Cancer Among Internship NCT03479359 | Changhai Hospital | — |
| Completed | Exercise Prescription Dose for Castration Resistance Prostate Cancer Patients NCT03526562 | University Hospital, Ghent | N/A |
| Terminated | Functional MR-guided Stereotactic Body Radiation Therapy of Prostate Cancer NCT01976962 | CancerCare Manitoba | N/A |
| Completed | Effect of PEEP on Arterial Oxygen Partial Pressure in Elderly Patients With Lithotomy Position Using LMA Supre NCT03390127 | Asan Medical Center | N/A |
| Completed | Innovations in the Treatment of Sexual Health Post Prostate Cancer Treatment: Comparing Mindfulness vs. CBT NCT03365518 | University of British Columbia | N/A |
| Completed | Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate C NCT03261999 | Foresee Pharmaceuticals Co., Ltd. | Phase 3 |
| Unknown | Multiparametric Ultrasound Imaging in Prostate Cancer NCT03101176 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | N/A |
| Completed | Machine-learning Optimization for Prostate Brachytherapy Planning NCT02943824 | Sunnybrook Health Sciences Centre | N/A |
| Completed | Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates o NCT03237416 | Bayer | Phase 1 |
| Unknown | Prostate Impendance Test Project NCT03428087 | University of Pisa | — |
| Completed | The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surg NCT03064308 | University of Nottingham | N/A |
| Active Not Recruiting | 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer NCT03173924 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Infectious Outcomes of Povidone-iodine Rectal Cleansing Plus Formalin Disinfection of Needle During Prostate B NCT03879486 | Hospital de Transplante Doutor Euryclides de Jesus Zerbini | N/A |
| Completed | Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT NCT03007732 | David Oh | Phase 2 |
| Unknown | Genetic Analysis of Prostate Cancer to Identify Predictive Markers of Disease Relapse or Metastatic Evolution NCT03421015 | University Hospital, Lille | — |
| Unknown | Clinic Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics NCT03094897 | Wuxi No. 4 People's Hospital | EARLY_Phase 1 |
| Active Not Recruiting | PSMA PET/CT for Assessment of Recurrent Prostate Cancer NCT02899312 | British Columbia Cancer Agency | — |
| Completed | PK, PD, Tolerability and Safety of MDPK67b in Healthy Volunteers NCT04839120 | Med Discovery SA | Phase 1 |
| Completed | Contrast Enhanced MRI of the Prostate NCT02245282 | OHSU Knight Cancer Institute | — |
| Completed | Incidence of Second Primary Malignancies in Prostate Cancer Patients With Bone Metastases - an Observational R NCT02963675 | Bayer | — |
| Terminated | Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer NCT02506114 | Lawrence Fong | Phase 2 |
| Completed | A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metast NCT02924766 | Janssen Research & Development, LLC | Phase 1 |
| Unknown | Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating T NCT02940977 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Unknown | A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Muta NCT02950064 | Placon Therapeutics | Phase 1 |
| Withdrawn | A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) NCT02905201 | Janssen Research & Development, LLC | — |
| Terminated | Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate NCT03066154 | The Netherlands Cancer Institute | Phase 1 |
| Completed | An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA- NCT02854436 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Stereotactic MR-guided Adaptive Radiation Therapy for Localized Prostate Cancer NCT03961321 | Amsterdam UMC, location VUmc | — |
| Terminated | Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy NCT02772562 | Medical University of South Carolina | Phase 2 |
| Completed | Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC NCT02952469 | University of Iowa | EARLY_Phase 1 |
| Unknown | Laser Fluorescence in Cancer Surgical Treatment NCT03021200 | Instituto do Cancer do Estado de São Paulo | N/A |
| Completed | Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC NCT02677376 | University of Wisconsin, Madison | — |
| Completed | Incidence of Second Primary Malignancies in Castration-Resistant Prostate Cancer: An Observational Retrospecti NCT02788409 | Bayer | — |
| Completed | A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, P NCT02813408 | Janssen Pharmaceutica N.V., Belgium | — |
| Terminated | Tumor Hypoxia With HX4 PET in Several Diseases NCT02584400 | Maastricht Radiation Oncology | Phase 2 |
| Completed | Effect of Intravenous Magnesium During Robot Assisted Prostatectomy NCT02833038 | Ajou University School of Medicine | N/A |
| Completed | Engaging Newly Diagnosed Men About Cancer Treatment Options NCT02668276 | University of Illinois at Chicago | N/A |
| Completed | Fasting and Nutritional Therapy in Patients With Advanced Metastatic Prostate Cancer NCT02710721 | Charite University, Berlin, Germany | N/A |
| Withdrawn | Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) NCT02647983 | Sunnybrook Health Sciences Centre | Phase 1 |
| Completed | Second Primary Cancers in Patients With Castration Resistant Prostate Cancer NCT02702908 | Bayer | — |
| Completed | Evaluation of Safety and Efficacy of Estetrol in Healthy Men NCT02718378 | Pantarhei Oncology B.V. | Phase 1 |
| Withdrawn | Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs NCT02621190 | Erasmus Medical Center | Phase 2 |
| Unknown | Determinants of Quality Of Life in AGEd Cancer Patients NCT02672657 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 NCT02712320 | Foresee Pharmaceuticals Co., Ltd. | Phase 3 |
| Completed | G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer NCT02381236 | GenSpera, Inc. | Phase 2 |
| Unknown | Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET NCT02631616 | Hadassah Medical Organization | Phase 1 |
| Terminated | Analysis of Cell-free DNA (cfDNA) in Men With Elevated PSA Levels NCT02771769 | Chronix Biomedical Corporation | — |
| Unknown | Impacts of Different Pressure Pneumoperitoneum on Myocardial and Pulmonary Injuries After Robot-assisted Surge NCT02600481 | Huadong Hospital | N/A |
| Terminated | A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrC NCT02616185 | Pfizer | Phase 1 |
| Terminated | Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer NCT02508636 | University of California, San Francisco | Phase 2 |
| Unknown | Hypofractionated Intensity Modulated and Image Guided Radiotherapy for Localized Prostate Cancer NCT02651896 | Hospital Sirio-Libanes | — |
| Unknown | CEUS Targeted Biopsies Compared to mpMRI Targeted and Systematic Biopsies for the Detection of Prostate Cancer NCT02831920 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | N/A |
| Active Not Recruiting | An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Pri NCT02531516 | Aragon Pharmaceuticals, Inc. | Phase 3 |
| Completed | Targeted Fusion Biopsy of the Prostate NCT02744534 | Emory University | Phase 2 |
| Terminated | Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer NCT02560051 | The University of Texas Health Science Center, Houston | Phase 2 |
| Terminated | Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer NCT02606123 | ESSA Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | A Registry of Participants With Prostate Cancer in Asia NCT02546908 | Janssen Research & Development, LLC | — |
| Completed | Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patie NCT02692976 | Radboud University Medical Center | Phase 2 |
| Completed | Impact on Quality of Life 3 Years After Diagnosis of Prostate Cancer NCT02854982 | Centre Hospitalier Universitaire de Nīmes | — |
| Completed | Preservation of Endopelvic Fascia: Effects on Postoperative Incontinence and Impotence. Randomized Clinical Tr NCT02526602 | Tampere University Hospital | N/A |
| Completed | Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonis NCT02475057 | Rabin Medical Center | Phase 4 |
| Terminated | Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer NCT02362451 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Feasibility Study for the Assessment of Sleep Quality in Men With Prostate Cancer Starting ADT NCT02919904 | Vancouver Prostate Centre | — |
| Completed | Gallium-68 Citrate PET Used in Prostate Cancer NCT02391025 | Rahul Aggarwal | EARLY_Phase 1 |
| Completed | Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previou NCT02362464 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Feasibility Study of Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer: Cyberknife vs. VMAT NCT02344667 | Juravinski Cancer Center | Phase 2 |
| Completed | Dose Escalation With SIB to Intraprostatic/Lymphatic GTV in High Risk Prostate Cancer NCT01962324 | Umeå University | N/A |
| Completed | Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRP NCT02363855 | Bayer | Phase 1 |
| Completed | Safety and Efficacy Study of Mix Vaccine in Prostate Carcinoma Patient NCT02338700 | Fuda Cancer Hospital, Guangzhou | Phase 1 / Phase 2 |
| Withdrawn | Irreversible Electroporation(IRE) For Unresectable Prostatic Neoplasms NCT02430649 | Fuda Cancer Hospital, Guangzhou | N/A |
| Completed | Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC) NCT02443571 | Blue Earth Diagnostics | — |
| Unknown | SmartTarget THERAPY NCT02290561 | University College, London | N/A |
| Unknown | Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer NCT02334579 | Swedish Medical Center | N/A |
| Active Not Recruiting | An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednis NCT02257736 | Aragon Pharmaceuticals, Inc. | Phase 3 |
| Active Not Recruiting | Prostate Cancer Biobank NCT04024475 | Swiss Cancer Institute | — |
| Unknown | Single Fraction HDR Brachytherapy Plus Hypofractionated EBRT for Low-risk Prostate Cancer: Phase II Trial NCT02283346 | AC Camargo Cancer Center | Phase 2 |
| Completed | PRIME - PRostate Imaging for Margin Evaluation NCT02151097 | Lightpoint Medical Limited | — |
| Completed | SmartTarget: BIOPSY NCT02341677 | University College, London | N/A |
| Unknown | Stereotactic Radiotherapy for Oligometastatic Prostate Cancer NCT02563691 | Sunnybrook Health Sciences Centre | Phase 1 / Phase 2 |
| Terminated | Pilot Study of SBRT and CDX-1127 in Prostate Cancer NCT02284971 | James Larner, MD | Phase 1 |
| Recruiting | Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer NCT02102477 | Olof Akre | N/A |
| Completed | Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer NCT02453009 | Santa Chiara Hospital | Phase 2 |
| Completed | A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Ur NCT02364531 | Janssen Inc. | — |
| Completed | Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Che NCT02217566 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carci NCT02234115 | Foresee Pharmaceuticals Co., Ltd. | Phase 3 |
| Completed | Supervised Group Based Exercise for Men With Prostate Cancer on Androgen Deprivation Therapy NCT02631681 | Herlev Hospital | N/A |
| Completed | 18F-DCFBC PET/CT in Prostate Cancer NCT02190279 | National Cancer Institute (NCI) | EARLY_Phase 1 |
| Active Not Recruiting | A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant NCT02123758 | Aragon Pharmaceuticals, Inc. | Phase 1 |
| Unknown | MRI / Ultrasound Fusion With Contrast-Enhanced Ultrasound Guidance NCT02233725 | University of British Columbia | Phase 1 |
| Active Not Recruiting | A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Inj NCT02266745 | Promontory Therapeutics Inc. | Phase 2 |
| Completed | Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy NCT02153918 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Interest of Indocyanine Green in Neoplastic Prostatic Tissue NCT02260349 | Centre Hospitalier Universitaire de Saint Etienne | Phase 3 |
| Completed | Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph N NCT02076503 | St. Olavs Hospital | N/A |
| Completed | Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer NCT02043678 | Bayer | Phase 3 |
| Completed | Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant NCT02023697 | Bayer | Phase 2 |
| Completed | A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzaluta NCT02034552 | Bayer | Phase 2 |
| Active Not Recruiting | Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer NCT02446405 | University of Sydney | Phase 3 |
| Completed | High-dose Vitamin D Supplementation for ADT-induced Side Effects NCT02064946 | University of Rochester | N/A |
| Active Not Recruiting | Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prost NCT02446444 | University of Sydney | Phase 3 |
| Completed | A Study for Patients With Prostate Cancer to See Whether Delivering an Extra Dose of Radiation to Parts of the NCT02004418 | AHS Cancer Control Alberta | Phase 1 / Phase 2 |
| Terminated | Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC NCT01995058 | Exelixis | Phase 2 |
| Terminated | Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Ca NCT02125617 | Kristoffer Rohrberg | — |
| Completed | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid T NCT02014337 | Corcept Therapeutics | Phase 1 |
| Completed | Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases NCT01934790 | Bayer | Phase 1 / Phase 2 |
| Completed | Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultras NCT02079025 | Exact Imaging | N/A |
| Recruiting | Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy NCT01834001 | National Cancer Institute (NCI) | — |
| Completed | Intrathecal Morphine in Robot-assisted Prostatectomy NCT01991275 | Seoul National University Hospital | N/A |
| Active Not Recruiting | A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer NCT01946204 | Aragon Pharmaceuticals, Inc. | Phase 3 |
| Completed | Japanese BAY88-8223 Monotherapy Phase II Study NCT01929655 | Bayer | Phase 2 |
| Completed | Study to Assess the Treatment Patterns in Metastatic Castration-Resistance Prostate Cancer (mCRPC) NCT02230059 | Janssen Research & Development, LLC | — |
| Terminated | Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer NCT01857817 | Vicus Therapeutics | Phase 2 |
| Completed | Effect of Modified Citrus Pectin on PSA Kinetics in Biochemical Relapsed PC With Serial Increases in PSA NCT01681823 | EcoNugenics | Phase 2 |
| Terminated | Protection of Rectum From High Radiation Doses Using a Spacer NCT01918605 | University of Oulu | N/A |
| Terminated | NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK NCT01816048 | University of Wisconsin, Madison | Phase 2 |
| Withdrawn | A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prost NCT01685489 | Bastyr University | Phase 1 |
| Completed | Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis NCT01810770 | Bayer | Phase 3 |
| Completed | Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR NCT02043184 | Michigan State University | N/A |
| Completed | Lymph Node Involvement Using Extended Pelvic Lymphadenectomy in Clinically Localized Prostate Cancer NCT02156414 | Javeriana University | — |
| Withdrawn | Focal Therapy for Prostate Cancer NCT01802307 | University of Maryland, Baltimore | Phase 2 |
| Enrolling By Invitation | Multiparametric MRI in Men With Prostate Cancer Undergoing Active Surveillance NCT02526797 | Herlev Hospital | — |
| Completed | Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer NCT01796028 | Centre Antoine Lacassagne | Phase 2 |
| Terminated | A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer NCT01647789 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Medico-economic Comparison of Robot-assisted Radical Prostatectomy Versus Radical Prostatectomy Via Laparotomy NCT01577836 | Centre Hospitalier Universitaire de Nīmes | N/A |
| Completed | First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer NCT01723475 | Bayer | Phase 1 |
| Active Not Recruiting | Curative Image Guided Radiotherapy for Prostate Cancer NCT01550237 | St. Olavs Hospital | N/A |
| Completed | Impact of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostat NCT01759836 | Asan Medical Center | Phase 2 |
| Completed | [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers NCT01717391 | John M. Buatti | Phase 2 |
| Completed | Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer NCT01683994 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer NCT01420965 | Augusta University | Phase 2 |
| Completed | Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response NCT01576029 | Sanofi | Phase 2 |
| Completed | Atorvastatin Before Prostatectomy and Prostate Cancer NCT01821404 | Tampere University Hospital | Phase 2 |
| Completed | Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With NCT01618370 | Bayer | Phase 3 |
| Completed | Hemi-Ablative Prostate Brachytherapy NCT02632669 | Royal Surrey County Hospital NHS Foundation Trust | N/A |
| Completed | Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Pr NCT01605227 | Exelixis | Phase 3 |
| Completed | Ion Prostate Irradiation NCT01641185 | Heidelberg University | Phase 2 |
| Completed | Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients NCT01565746 | Bayer | Phase 1 |
| Terminated | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic C NCT01522443 | Exelixis | Phase 3 |
| Completed | Health Effects of Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation Therapy NCT01711892 | University of Copenhagen | N/A |
| Completed | AMG 386 and Abiraterone for Advanced Prostate Cancer NCT01553188 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Prostate Accurately Targeted Radiotherapy Investigation of Overall Treatment Time NCT01423474 | CancerCare Manitoba | N/A |
| Completed | Vascular Changes Of Patients Undergoing Laparoscopic Radical Prostatectomy NCT03241758 | Corporacion Parc Tauli | — |
| Completed | Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer NCT01446731 | Inge Marie Svane | Phase 2 |
| Active Not Recruiting | MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness NCT01464216 | Oslo University Hospital | — |
| Completed | Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer NCT01441713 | Copenhagen University Hospital at Herlev | — |
| Completed | MR Image Guided Therapy in Prostate Cancer NCT01377753 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Evaluation of Modern MRI in the Diagnosis of Prostate Cancer in a Danish Setup NCT01640262 | Copenhagen University Hospital at Herlev | — |
| Terminated | Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer NCT01335204 | Medical University of South Carolina | Phase 1 / Phase 2 |
| Terminated | A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer NCT01545882 | Ottawa Hospital Research Institute | Phase 2 |
| Terminated | Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy NCT01365143 | Mayo Clinic | Phase 4 |
| Completed | Evaluation of Diagnostic Value of 3-T Magnetic Resonance Imaging (MRI) in Suspected Prostate Cancer NCT01357512 | University of Oulu | N/A |
| Completed | A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer NCT01288911 | Astellas Pharma Inc | Phase 2 |
| Completed | Outpatient Radical Prostatectomy - Surgical and Anesthetic Considerations NCT01955863 | Wesley Justino Magnabosco | N/A |
| Completed | A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer NCT01306890 | Dendreon | — |
| Terminated | Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of NCT01132404 | Millennium Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | Vitamin C as an Anti-cancer Drug NCT01080352 | Copenhagen University Hospital at Herlev | Phase 2 |
| Completed | Testing Decision Aids About Early Stage Prostate Cancer NCT02053389 | University of Michigan | N/A |
| Active Not Recruiting | Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progre NCT01653925 | CHU de Quebec-Universite Laval | N/A |
| Completed | Study to Find Maintenance Dose for Periodic Administration of ASP3550 NCT01261572 | Astellas Pharma Inc | Phase 2 |
| Terminated | Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy NCT01450683 | Stanford University | Phase 2 |
| Unknown | Quality of Life in Men Undergoing Robotic Assisted Laparoscopic Radical Prostatectomy Versus Radical Retropubi NCT01173952 | Samsung Medical Center | — |
| Completed | CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS) NCT01206036 | Central European Society for Anticancer Drug Research | Phase 1 / Phase 2 |
| Completed | Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer NCT01186484 | Janssen Pharmaceutical K.K. | Phase 1 |
| Completed | A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostat NCT01095848 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | Phase 1 |
| Terminated | Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients NCT01076751 | Sanofi | — |
| Terminated | Study to Evaluate the Clinical Impact of a Laparoscopic Radical Prostatectomy Simulator NCT00999960 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Aggressive Prostate Cancers in Elderly Patients NCT01347476 | Seoul National University Hospital | — |
| Recruiting | Institut Paoli Calmettes Prostate Cancer Database NCT02869594 | Institut Paoli-Calmettes | — |
| Terminated | Figitumumab Combined With Pegvisomant For Advanced Solid Tumors NCT00976508 | Pfizer | Phase 1 |
| Completed | Symptoms and Quality of Life (QoL) After Palliative Pelvic Radiation of Prostate and Rectal Cancers NCT01023529 | Sorlandet Hospital HF | — |
| Terminated | Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer NCT01020305 | Sandy Srinivas | Phase 1 / Phase 2 |
| Completed | Clinical Evaluation of the PROGENSA(Registered Trademark) Prostate Cancer Gene 3 (PCA3) Assay in Men With a Pr NCT01024959 | Gen-Probe, Incorporated | N/A |
| Unknown | Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer NCT00906269 | Hartford Hospital | Phase 4 |
| Completed | Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors NCT00962494 | Stanford University | Phase 2 |
| Completed | Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate C NCT00917748 | Sanofi | Phase 3 |